0001171000-15-000045.txt : 20150702 0001171000-15-000045.hdr.sgml : 20150702 20150702133257 ACCESSION NUMBER: 0001171000-15-000045 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150701 FILED AS OF DATE: 20150702 DATE AS OF CHANGE: 20150702 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lismore Damian T. CENTRAL INDEX KEY: 0001560864 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 15968506 MAIL ADDRESS: STREET 1: 12270 WILKINS AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20852 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-07-01 0001618561 Nexvet Biopharma plc NVET 0001560864 Lismore Damian T. C/O NEXVET BIOPHARMA PLC NIBRT; FOSTERS AVENUE, MOUNT MERRION BLACKROCK, CO. DUBLIN L2 IRELAND 0 1 0 0 CHIEF FINANCIAL OFFICER Ordinary Shares 2015-07-01 4 M 0 4000 .125 A 10000 D Ordinary Shares 13724 I Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C> Ordinary Shares 7080 I By spouse Options to Purchase Stock .125 2015-07-01 4 M 0 4000 0 D 2015-07-01 2019-07-01 Ordinary Shares 4000 14000 D The reporting person and his spouse share voting and dispositive power with respect to these reported securities. 4,000 options vested and became exercisable on 7/1/15; 4.000 options shall vest and become exercisable on each of 7/1/16 and 7/1/17. The remaining 6,000 options will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors; such completion must occur on or before 7/1/19 /s/ Damian Lismore by Geraldine T. Farrell, Attorney-in-Fact 2015-07-02